Company: BNBX
Filing Date: 2025-11-04
Form Type: 424B5
Source: 0001104659-25-105958
Chunk: 49

Company: BNB PLUS CORP.
Filing Date: 2025-11-04
Form: 424B5
Chunk 49
---
 them. See “Plan of Distribution.”

In this prospectus, unless otherwise indicated, the “Registrant,”
“our company,” “we,” “us” or “our” refer to Applied DNA Sciences, Inc., a Delaware corporation
and its consolidated subsidiaries.

<div align='center'>1

PROSPECTUS SUMMARY</div>

This prospectus summary highlights certain information about our company and other information contained elsewhere in this prospectus or in documents incorporated by reference. This summary does not contain all of the information that you should consider before making an investment decision. You should carefully read the entire prospectus, any prospectus supplement, including the section entitled “Risk Factors” and the documents incorporated by reference into this prospectus, before making an investment decision.

<div align='center'>THE OFFERING</div>

This prospectus is part of a Registration Statement that we filed with
the SEC utilizing a shelf registration process. Under this shelf registration process, we may sell any combination of:

| ● | common stock;                                                        |
| ● | preferred stock;                                                     |
| ● | debt securities, in one or more series;                              |
| ● | warrants to purchase any of the securities listed above;             |
| ● | rights to purchase common stock, preferred stock or warrants; and/or |
| ● | units consisting of one or more of the foregoing                     |

in one or more offerings up to a total dollar amount of $75,000,000.
This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide
a prospectus supplement that will contain specific information about the terms of that specific offering and include a discussion of any
risk factors or other special considerations that apply to those securities. The prospectus supplement may also add, update or change
information contained in this prospectus. You should read both this prospectus and any prospectus supplement together with the additional
information described under the heading “Where You Can Find More Information.”

<div align='center'>OUR COMPANY</div>

Overview

We are a biotechnology
company developing and commercializing technologies to produce and detect DNA. Using the polymerase chain reaction (“PCR”)
to enable both the production and detection of DNA, we operate in three primary business markets: (i) the manufacture of synthetic DNA
for use in the manufacture of nucleic acid-based therapeutics (“Therapeutic DNA Production Services”); (ii) the detection
of DNA in molecular diagnostics and genetic testing services (“MDx Testing Services